This inventor holds 1 USPTO granted patent. Top assignee: Ferring B.v.. Active years: 1999.
Company Filing History:
Years Active: 1999
Title: Jerzy A Trojnar: Innovator in Opioid Peptide Research
Introduction
Jerzy A Trojnar is a notable inventor based in Solana Beach, California. He has made significant contributions to the field of opioid peptide research, particularly focusing on kappa receptor opioid peptides. His work has implications for pain management and therapeutic applications.
Latest Patents
Trojnar holds a patent for "Kappa receptor opioid peptides." This invention involves peptides that exhibit high selectivity for the kappa opioid receptor (KOR) and demonstrate a long duration of peripheral action without significant entry into the brain. The peptides are sequences of four D-isomer amino acid residues with a C-terminus that is a mono or di-substituted amide. Representative compounds from this patent have an affinity for the KOR that is at least 1,000 times greater than their affinity for the mu opioid receptor, with an ED.sub.50 of not greater than about 0.5 mg/kg.
Career Highlights
Throughout his career, Trojnar has been associated with Ferring B.V., where he has contributed to innovative research and development in the pharmaceutical sector. His work has been instrumental in advancing the understanding of opioid receptors and their potential therapeutic uses.
Collaborations
Trojnar has collaborated with notable colleagues, including Pierre Jm Riviere and Jean Louis Junien. These collaborations have fostered a productive research environment, leading to advancements in opioid peptide studies.
Conclusion
Jerzy A Trojnar's contributions to opioid peptide research highlight his innovative spirit and dedication to improving therapeutic options. His patent on kappa receptor opioid peptides represents a significant advancement in the field, showcasing the potential for targeted pain management solutions.